28 January 2026
28 January 2026
QT Imaging data will be enabled for clinical interpretation by incorporating Olea Medical’s analytics technologies.
The therapy is designed to silence both PCSK9 and APOC3 genes simultaneously.
Qilu Pharmaceutical will oversee subsequent development and commercialisation activities.
The trial will enrol up to 70 patients with refractory glaucoma and has a 12-month primary effectiveness endpoint.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
